FibroGen Inc

NASDAQ:FGEN  
13.79
+0.30 (+2.22%)
Products

Fibrogen Exercises Exclusive License Option For Hifibio’S CCR8 Program

Published: 12/20/2021 13:33 GMT
FibroGen Inc (FGEN) - Fibrogen Exercises Exclusive License Option for Hifibio’s Ccr8 Program.
Fibrogen Inc - Hifibio to Receive $35 Million Option Exercise Payment, Potential Milestones and Royalties.
Fibrogen Inc - Hifibio Will Also Be Eligible to Receive Royalties Based Upon Net Sales.
Fibrogen Inc - Development Candidate is Expected to Enter Clinical Development in 2023.
Fibrogen Inc - Will Have Sole Right to Develop All Products in Ccr8 Program Worldwide.